Skip to content

Validation of homoeopathic drugs for bronchial asthma

Validation of commonly used homoeopathic drugs for bronchial asthma: A prospective observational study

Status
Recruiting
Phases
Phase 3
Study type
Observational
Source
CTRI
Registry ID
CTRI/2018/04/013152
Enrollment
200
Registered
2018-04-10
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Bronchial Asthma

Interventions

Sponsors

Central Council for Research in Homoeopathy New Delhi Ministry of AYUSH Government of India
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Willing to report for follow up even after most troublesome symptom(s) are gone. 2. Consider a diagnosis of asthma and perform spirometry if any of these indicators are present: a. The symptoms of dyspnoea, cough and/or wheezing, especially nocturnal, difficulty in breathing or chest tightness; b. With acute episodes: hyperinflation of thorax, decreased breath sounds, high pitched wheezing, and use of accessory muscles; c. Symptoms worse in presence of exercise, viral infections, inhaled allergens, irritants, changes in weather, strong emotional expression, stress, menstrual cycles; d. Reversible airflow obstruction: FEV1 >12% or >200 ml from baseline or increase in FEV1 >10% of predicted after inhalation of bronchodilator, if able to perform spirometry.

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating women 2. Other diseases causing pulmonary obstruction 3. Other associated pathologies (like heart diseases, T.B.) 4. On allopathic drugs, other than for hypertension or diabetes mellitus 5. Other ongoing treatment which is likely to interfere with the course of this treatment.

Design outcomes

Primary

MeasureTime frame
To observe the change in spirometry measurement FEV1, in all patients more than 5 years old when asthma is stable at the end of 1 year of treatment.Timepoint: Baseline, 1 year

Secondary

MeasureTime frame
1. To observe the change in spirometry measurements (FVC, FEV1/FVC) in all patients more than 5 years old when asthma is stable at the end of 1 year of treatment. 2. To observe the change in Asthma symptom utility index at the end of 1 year of treatment. 3. To observe the change in Quality of life (WHO-QoL) score at end of 1 year of treatment. Timepoint: Baseline, 1 year

Countries

India

Contacts

Public ContactDr R K Manchanda

Central Council for Research in Homoeopathy

anilnaman@rediffmail.com011-28524266

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026